Trametinib

Trametinib is an IEC inhibitor drug with anticancer activity. MEK1 and MEK2 inhibitors. Trametinib has shown good results in phase III clinical trials in metastatic melanoma with BRAF V600E mutation.  

API&Intermediates CAS Structural formula Drug Minimum order quantity
1 N-3,3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-5-hydroxy-6,8-di 871700-24-2 Intermediate 5g
2 3-Cyclopropyl-1-(2-fluoro-4-iodophenyl)-6-(methylamino)pyrim 871700-22-0 Intermediate 5g
3 Trametinib 871700-17-3 API 5g
    Contact
  • Company Tel:022-28219283
  • Email:info@holder-pharm.com
Copyright©2020 Tianjin Holder Pharmaceutical Technology Co., Ltd. .All rights reserved.
Address:Building 6, Hengze Industrial Park, Jinnan District, Tianjin